What is the role of secondary venous thromboembolism prophylaxis in antiphospholipid syndrome (APS)?
EULAR recommendations for the management of antiphospholipid syndrome in adults:
2021 Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report:
Regarding the use of DOACs in APS:
- If a patient with triple-positive antiphospholipid syndrome (APS) presents with VTE, then VKA is favored over DOAC therapy. If such a patient is initiated on a DOAC, then panel consensus exists for transitioning to VKA therapy.
Learn more here.